$HALO (HALOZYME THERAPEUTICS) — 8-K: Halozyme proposes $1.05 billion convertible senior notes offering due 2033

Halozyme Therapeutics announced a proposed offering of $1.05 billion aggregate principal amount of convertible senior notes due October 1, 2033, with an option for initial purchasers to buy up to an additional $150 million. The notes are senior, unsecured obligations accruing interest payable semi-annually, with conversion terms to be set at pricing. Net proceeds will fund capped call transactions, repurchases of its outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028, and general corporate purposes including working capital, capital expenditures, and potential acquisitions.

Halozyme Therapeutics announced a proposed offering of $1.05 billion aggregate principal amount of convertible senior notes due October 1, 2033, with an option for initial purchasers to buy up to an a